A new membership program, SmartRx, offers consumers savings on prescriptions, as well as office visits, eye care, vaccines and pet meds.
A new prescription discount card, SmartRx, a division of Smarty, joins GoodRx and SingleCare in the prescription discount card arena. SmartRx offers its users a free discount card and a paid membership program. The SmartRx Discount Card helps consumers save up to 80% on their prescription drugs. SmartRx+ is a monthly membership program that offers rebates for doctor or dentist visits, telehealth care, prescription glasses or contacts, annual vaccines, and pet medications.
“An increase in healthcare costs over the past few years coupled with this past year’s inflation rates have really affected consumer’s bottom line. SmartRx is a smart healthcare cost saving solution that goes beyond prescription drug costs to help tackle these consumer concerns about health care costs,” Vipin Porwal, chief executive officer and founder of Smarty and SmartRx, told Formulary Watch.
SmartRx works with PBMs to pass on discounts when consumers present their SmartRx coupon or discount card at the pharmacy, Porwal said.
The membership rate for SmartyRx+ is $19 per month after a seven-day trial for $3. Users get a $15 cashback bonus rebate on their first prescription purchase, plus $30 annual rebate for vaccines, $50 a month for doctor and dental visits, $125 for annual for prescription glasses and contacts, $25 a month for pet medications, and other rebates.
In addition, the SmartRx Discount Card is accepted at more than 65,000 pharmacies nationwide.
In a recent SmartRx survey, 66% of respondents agreed or strongly agreed that prescriptions are too costly. Nearly half (48%) of respondents said they would use a subscription service that offers cashback and rebates on prescriptions.
Smarty is an online shopping destination that automatically applies the best coupon on purchases from more than 6,000 U.S. retailers and 1,500 global merchants.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More